Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:715623.
doi: 10.1155/2011/715623. Epub 2011 Aug 17.

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Junichi Seike  1 , Toru Sawada, Naoya Kawakita, Yota Yamamoto, Yasuhiro Yuasa, Hiromichi Yamai, Hirokazu Takachi, Takahiro Yoshida, Akira Tangoku
Affiliations

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Junichi Seike et al. Int J Surg Oncol. 2011.

Abstract

Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We investigated the efficacy of rikkunshito (TJ-43) on CINV. Methods. Nineteen patients who were going to undergo DFP therapy were enrolled. They were assigned to the following two groups: a TJ-43-treated group and -nontreated group. The following parameters were compared between the 2 groups: (1) the frequency of symptoms occurred, (2) vomiting, nausea, and anorexia score, and (3) QOL score. Results. The incidence of symptoms was lower in the TJ-43-treated group than that in the control group. The nausea score of the TJ-43-treated group was significantly lower than that of the control group. In the QOL score, the mood score and the ADL score decreased significantly in the control group. Conclusion. We recommend TJ-43 administration in patients undergoing DFP chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interview sheet of QOL.
Figure 2
Figure 2
Enrollment and randomization of study patients.
Figure 3
Figure 3
Time-course changes in score of nausea. Each plot refers to mean ± SD. ∗: Significant difference of the score deterioration between the TJ-43 treated group and the TJ-43 non-treated group (P  < 0.05, Wilcoxon's rank sum test).
Figure 4
Figure 4
Time-course changes in score of vomiting. Each plot refers to mean ± SD. There were no significant differences in score change between the TJ-43 treated group and the TJ-43 non-treated group (Wilcoxon's rank sum test).
Figure 5
Figure 5
Time-course changes in score of anorexia. Each plot refers to mean ± SD. There were no significant differences in score change between the TJ-43 treated group and the TJ-43 non-treated group (Wilcoxon's rank sum test).
Figure 6
Figure 6
Change in score of mood. Each plot refers to mean ± SD. *Significant difference between the score on day 1 and day 14 in the TJ-43 non-treated group (P < 0.05, Wilcoxon's signed rank test).
Figure 7
Figure 7
Changes in score of ADL. Each plot refers to mean ± SD. *Significant difference between the score on day 1 and day 14 in the TJ-43 non-treated group (P  < 0.05, Wilcoxon's signed rank test).
Figure 8
Figure 8
Change in QOL score of mood or ADL after the 2-week treatment. Each column represents the mean ± SD. *Significant difference of the change in QOL score between the TJ-43 treated group and the TJ-43 non-treated group (P < 0.05, Wilcoxon's rank sum test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mortality Rate by Cancer Site, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan, http://www.ncc.go.jp/
    1. Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Ishikawa T, Itabashi M. Superficial esophageal carcinoma. Surgical treatment and the results. Cancer. 1990;66(11):2319–2323. - PubMed
    1. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Annals of Surgery. 1994;220(3):364–373. - PMC - PubMed
    1. Tabira Y, Yasunaga M, Nagamoto N, et al. Quality of life after esophagectomy for cancer: an assessment using the questionnaire with the face scale. Surgery Today. 2002;32(3):213–219. - PubMed
    1. Muro K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, et al. A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906) Journal of Clinical Oncology. 2007;25(18s, supplement) ASCO Annual Meeting, abstract no. 15137.

LinkOut - more resources